PAYS - Paysign: Expect Rapid Growth In Its Pharma Business

2024-06-30 01:35:07 ET

Summary

• Shares have risen sharply this year, reflecting solid business performance.
• Its pharma segment is experiencing exceptional growth and has a long runway for continued expansion.
• My valuation model indicates that shares have limited upside.

Investment thesis

Paysign's ( PAYS ) mature plasma donor payment business has shown solid profitable growth in recent quarters. As its growth is expected to moderate going forward, the cash flows generated are being allocated to fund the patient affordability programs in its pharma business, which has recently experienced exceptional growth. Additionally, the pharma business segment has a long runway for continued expansion....

For further details see: